Vanguard Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-4,178,440
| Closed | -$101M | – | 4622 |
|
|
2023
Q1 | $101M | Buy |
4,178,440
+35,696
| +0.9% | +$448K | ﹤0.01% | 1830 |
|
|
2022
Q4 | $43.8M | Buy |
4,142,744
+538,679
| +15% | +$4.35M | ﹤0.01% | 2247 |
|
|
2022
Q3 | $16.2M | Buy |
3,604,065
+1,027,113
| +40% | +$4.68M | ﹤0.01% | 2720 |
|
|
2022
Q2 | $10.3M | Buy |
2,576,952
+25,139
| +1% | +$119K | ﹤0.01% | 2977 |
|
|
2022
Q1 | $18.7M | Buy |
2,551,813
+54,980
| +2% | +$329K | ﹤0.01% | 2818 |
|
|
2021
Q4 | $14M | Sell |
2,496,833
-162,914
| -6% | -$1.03M | ﹤0.01% | 3038 |
|
|
2021
Q3 | $17M | Buy |
2,659,747
+17,364
| +0.7% | +$112K | ﹤0.01% | 2948 |
|
|
2021
Q2 | $22.3M | Sell |
2,642,383
-182,071
| -6% | -$1.47M | ﹤0.01% | 2783 |
|
|
2021
Q1 | $29.6M | Buy |
2,824,454
+539,350
| +24% | +$7.59M | ﹤0.01% | 2597 |
|
|
2020
Q4 | $38.7M | Buy |
2,285,104
+84,652
| +4% | +$1.27M | ﹤0.01% | 2327 |
|
|
2020
Q3 | $28.2M | Buy |
2,200,452
+67,428
| +3% | +$852K | ﹤0.01% | 2295 |
|
|
2020
Q2 | $30.1M | Buy |
2,133,024
+720,415
| +51% | +$9.1M | ﹤0.01% | 2235 |
|
|
2020
Q1 | $13M | Buy |
1,412,609
+52,920
| +4% | +$682K | ﹤0.01% | 2492 |
|
|
2019
Q4 | $20.3M | Buy |
1,359,689
+28,816
| +2% | +$257K | ﹤0.01% | 2528 |
|
|
2019
Q3 | $9.08M | Buy |
1,330,873
+451,872
| +51% | +$4.57M | ﹤0.01% | 2863 |
|
|
2019
Q2 | $10.6M | Buy |
879,001
+392,383
| +81% | +$2.14M | ﹤0.01% | 2824 |
|
|
2019
Q1 | $1.12M | Buy |
486,618
+600
| +0.1% | +$1.41K | ﹤0.01% | 3595 |
|
|
2018
Q4 | $860K | Sell |
486,018
-226,884
| -32% | -$652K | ﹤0.01% | 3608 |
|
|
2018
Q3 | $2.86M | Buy |
+712,902
| New | +$2.82M | ﹤0.01% | 3416 |
|
Other funds holding PRVB
Vanguard Group's PRVB Position: Q2 2023 in Review
Vanguard Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 4,178,440 shares — an estimated $101M sold.
Vanguard Group first reported a position in PRVB in Q3 2018 and held it in 19 quarters. The position peaked at $101M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Vanguard Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Vanguard Group sold 4,178,440 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $101M.
- Vanguard Group first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 19 quarters.
- Vanguard Group's Provention Bio, Inc. Common Stock position peaked at $101M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.